Neurological disorders affect hundreds of millions of people worldwide, and for many patients, existing treatments fall short. Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is working to change that with a pipeline targeting two significant areas of unmet neurological need: multiple sclerosis and the acute effects of alcohol intoxication.
Multiple sclerosis (MS) is one of the most common and debilitating neurological diseases affecting young adults. An estimated 2.9 million people are living with MS worldwide, with about one million of those in the United States. The disease is most often diagnosed between ages 20 and 50, with a mean age of 32 globally, and affects females at roughly twice the rate of males. Quantum BioPharma's focus for MS is Lucid-MS, a patented new chemical entity that takes a fundamentally different approach from existing therapies. Supporting Lucid-MS's phase 2 development is an ongoing imaging collaboration with Massachusetts General Hospital.
In addition to MS, Quantum BioPharma has developed unbuzzd, a proprietary dietary supplement formulated to support alcohol metabolism and reduce the acute effects of intoxication and hangover. This product addresses the widespread issue of alcohol-related impairment, offering a potential solution for millions who experience the negative cognitive and physiological impacts of alcohol.
The company's dual-pronged strategy highlights its commitment to addressing conditions that have limited treatment options. For more information on Quantum BioPharma, visit their newsroom at https://ibn.fm/QNTM.
These developments come as the biopharmaceutical industry increasingly focuses on neurological disorders, which represent a growing burden on global health systems. Quantum BioPharma's approach, combining a novel MS therapy with a consumer-focused supplement for alcohol metabolism, positions it uniquely in the market.
The company's efforts are part of a broader trend in biotechnology to address diseases that have historically been difficult to treat. With Lucid-MS and unbuzzd, Quantum BioPharma is aiming to provide new options for patients and consumers alike.
